JNJ · Forward model · MedTech Cardiovascular
What has to happen in MedTech Cardiovascular
Model as of
This page changes MedTech Cardiovascular inside the complete JNJ model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.
Shares this vertical and portfolio case. Slider and horizon edits stay in your browser.
MedTech Cardiovascular
Basis quarter$2.40B
Final quarter$3.08B
Implied CAGR+5%
Final revenue mix9%
Electrophysiology plus the acquired Abiomed and Shockwave platforms; the fastest MedTech line, but the last two years of growth are substantially acquired.
Last four quarters
2025 Q3
$2.21B
Reported
2025 Q4
$2.30B
Reported
2026 Q1
$2.38B
Reported
2026 Q2
$2.40B
Reported
ElectrophysiologyAbiomed / heart recoveryShockwave / IVLOther cardiovascular
Sequential growth
+1.1%/qtr
decaying toward +1.4%
1.1% a quarter, sized on the +3.9% print after Shockwave anniversaried, not the +10.1% TTM.
MedTech Cardiovascular
Latest: $3.08B (2031Q2E)
| Period | Value |
|---|---|
| 2023Q1 | $1.50B |
| 2023Q2 | $1.62B |
| 2023Q3 | $1.56B |
| 2023Q4 | $1.67B |
| 2024Q1 | $1.81B |
| 2024Q2 | $1.87B |
| 2024Q3 | $1.97B |
| 2024Q4 | $2.06B |
| 2025Q1 | $2.10B |
| 2025Q2 | $2.31B |
| 2025Q3 | $2.21B |
| 2025Q4 | $2.30B |
| 2026Q1 | $2.38B |
| 2026Q2 | $2.40B |
| 2026Q3E | $2.43B |
| 2026Q4E | $2.46B |
| 2027Q1E | $2.49B |
| 2027Q2E | $2.51B |
| 2027Q3E | $2.54B |
| 2027Q4E | $2.58B |
| 2028Q1E | $2.61B |
| 2028Q2E | $2.64B |
| 2028Q3E | $2.67B |
| 2028Q4E | $2.71B |
| 2029Q1E | $2.74B |
| 2029Q2E | $2.77B |
| 2029Q3E | $2.81B |
| 2029Q4E | $2.85B |
| 2030Q1E | $2.88B |
| 2030Q2E | $2.92B |
| 2030Q3E | $2.96B |
| 2030Q4E | $3.00B |
| 2031Q1E | $3.04B |
| 2031Q2E | $3.08B |
Assumptions & reasoning
- Growth decelerated from +22.3% trailing-twelve-month a year ago to +10.1% now and +3.9% in the latest quarter as the Shockwave acquisition anniversaried. The forward rate is sized on the latest quarter, not the trailing year.
- Left aseasonal: the 4.5% amplitude is inside a 5.3% worst-quarter spread, and the Shockwave close in May 2024 sits exactly on the Q2 index that the measured shape leans on.